Methods and compositions relating to an engineered peptide capable of binding to a biological molecule for viral inhibition. The engineered peptide is computationally-derived from soluble angiotensin-converting enzyme 2 (sACE2), a known receptor for viral spike proteins. The engineered peptide is optimized for minimal size and off-target effects. The engineered sACE2 peptide variants are a suitable targeting domain for fusion proteins of various effects.

Provided herein, in some aspects, are polypeptide monomers comprising an angiotensin-converting enzyme 2 (ACE2) ectodomain and an oligomerization domain. Also provided herein are oligomeric complexes comprising ACE2 monomers. Methods of using such to monomers and oligomeric complexes for the diagnosis, prevention, and treatment of viral infections such as the coronavirus are also provided.

A method for inhibiting infection of SARS-CoV-2 in a subject is provided, comprising administering an effective amount of plant extract, wherein the plant extract comprises an alcohol extract of the herbal of Menispermaceae, wherein the herbal of Menispermaceae is Stephania cepharantha or Stephania tetrandra.

The present disclosure relates to fusion protein compositions and methods of reducing and treating viral infections. The fusion proteins include a polypeptide comprising a b1 domain, or a derivative or fragment thereof, of a neuropilin; an ACE2 domain, or a derivative or a fragment thereof, of an angiotensin converting enzyme 2; and or an immunoglobulin domain. Both the b1 and ACE2 domains are capable of binding to a coat protein of a virus selected from the group consisting of herpesviridae, papillomaviridae, coronaviridae, flaviviridae, togaviridae, bomaviridae, bunyaviridae, filoviridae, orthomyxoviridae, paramyxoviridae, pneumoviridae, and retro viridae. In some embodiments, the b1 domain, or a derivative or fragment thereof, and/or the (ACE2) domain, can be used to specifically bind S proteins of COVID-19 particles.

The present invention provides polypeptides with coronavirus neutralising capacity. It further provides nucleic acids, vectors, cells, pharmaceutical compositions and medical uses that exploit the polypeptides of the invention

Protein biosensors and methods of using these sensors to detect anti-SARS-CoV-2 patient antibodies (Abs) in a solution-based, rapid, and quantitative COVID-19 serological assay are provided. In certain aspects, the sensors each comprise a first fusion protein that comprises a first SARS-CoV-2 viral protein and a first peptide fragment of a split reporter protein, and a second fusion protein that comprises a second fusion protein that comprises a second SARS-CoV-2 viral protein domain and a second peptide fragment of the split reporter protein. Only if the test sample comprise SARS-CoV- antibodies, the first and second peptide fragments associate to produce an enzymatically active reporter protein.

The disclosure herein relates to novel antibodies and antigen binding fragments that are used in the treatment, prevention and diagnosis of COVID-19, the disease caused by SARS-CoV-2. The complete polypeptide and nucleic acid consensus sequences of the antibodies and antigen binding fragments disclosed herein are reconstructed in silico.

The present disclosure provides methods and compositions for high frequency, targeted mammalian transgenesis using, for example, a two-step, two-stage process that enables integrating anywhere in the mammalian genome large pieces of nucleic acid in single generation.

Provided herein, in some aspects, are polypeptide monomers comprising an angiotensin-converting enzyme 2 (ACE2) ectodomain and an oligomerization domain. Also provided herein are oligomeric complexes comprising ACE2 monomers. Methods of using such to monomers and oligomeric complexes for the diagnosis, prevention, and treatment of viral infections such as the coronavirus are also provided.

This document provides adenovirus vectors and methods and materials related to using adenovirus vectors. For example, adenoviruses for delivering nucleic acid encoding one or more immunogens (e.g., one or more immunogens associated with a pathogen causing an infection) to cells within a mammal such that the mammal produces an effective immune response against the immunogen(s) are provided.